Skip to content
10-Q

Quarterly Report

Ocular Therapeutix, Inc. OCUL

0001558370-25-006225

← back to feed
Filed
May 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 159.3M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $37.93M
Current Liabilities Q1 2025 · Dec 31, 2024 $41.35M
Total Liabilities Q1 2025 · Mar 31, 2025 $139.99M
Total Liabilities Q1 2025 · Dec 31, 2024 $142.59M
Current Assets Q1 2025 · Mar 31, 2025 $387.69M
Current Assets Q1 2025 · Dec 31, 2024 $440.99M
Total Assets Q1 2025 · Mar 31, 2025 $405.92M
Total Assets Q1 2025 · Dec 31, 2024 $457.94M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $392.1M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $482.89M
Shares Diluted Q1 2025 · Mar 31, 2024 132.02M sh
Capex Q1 2025 · Mar 31, 2024 $255K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$33.89M
Stockholders Equity Q1 2025 · Mar 31, 2024 $407.98M
Stockholders Equity Q1 2025 · Dec 31, 2023 $91.13M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.49
Eps Basic Q1 2025 · Mar 31, 2024 −$0.49
Sga Expense Q1 2025 · Mar 31, 2024 $14.15M
Rd Expense Q1 2025 · Mar 31, 2024 $20.74M
Net Income Q1 2025 · Mar 31, 2024 −$64.85M
Operating Income Q1 2025 · Mar 31, 2024 −$31.62M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $1.33M
Revenue Q1 2025 · Mar 31, 2024 $14.77M